Johnson & Johnson (NYSE:JNJ) is Northern Capital Management Inc.’s 6th Largest Position

Northern Capital Management Inc. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 20,317 shares of the company’s stock after acquiring an additional 201 shares during the quarter. Johnson & Johnson makes up 2.2% of Northern Capital Management Inc.’s investment portfolio, making the stock its 6th biggest position. Northern Capital Management Inc.’s holdings in Johnson & Johnson were worth $3,214,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Christopher J. Hasenberg Inc purchased a new position in Johnson & Johnson during the first quarter worth about $31,000. Keener Financial Planning LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $40,000. WFA Asset Management Corp boosted its stake in shares of Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $44,000. Finally, Disciplined Equity Management Inc. purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $45,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on JNJ shares. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. The Goldman Sachs Group lowered their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. TD Cowen decreased their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Finally, TD Securities decreased their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $173.00.

Johnson & Johnson Stock Down 1.5 %

JNJ stock traded down $2.34 during midday trading on Tuesday, reaching $151.90. 1,963,172 shares of the company were exchanged, compared to its average volume of 7,291,422. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The stock’s 50-day simple moving average is $148.42 and its 200 day simple moving average is $153.24. The company has a market cap of $365.57 billion, a price-to-earnings ratio of 9.47, a price-to-earnings-growth ratio of 2.85 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.79%. The company had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter last year, the company earned $2.80 earnings per share. The firm’s revenue for the quarter was up 4.3% on a year-over-year basis. On average, equities analysts forecast that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.27%. Johnson & Johnson’s payout ratio is 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.